Related references
Note: Only part of the references are listed.An international consensus approach to the management of atypical hemolytic uremic syndrome in children
Chantal Loirat et al.
PEDIATRIC NEPHROLOGY (2016)
A national specialized service in England for atypical haemolytic uraemic syndrome-the first year's experience
N. S. Sheerin et al.
QJM-AN INTERNATIONAL JOURNAL OF MEDICINE (2016)
Impact of eculizumab treatment on paroxysmal nocturnal hemoglobinuria: a treatment versus no-treatment study
Michael Loschi et al.
AMERICAN JOURNAL OF HEMATOLOGY (2016)
Discontinuation of Eculizumab in a Patient With Atypical Hemolytic Uremic Syndrome Due to a Mutation in CFH
Sandra Habbig et al.
AMERICAN JOURNAL OF KIDNEY DISEASES (2016)
Novel biomarker and easy to perform ELISA for monitoring complement inhibition in patients with atypical hemolytic uremic syndrome treated with eculizumab
Magdalena Riedl et al.
JOURNAL OF IMMUNOLOGICAL METHODS (2016)
Glomerular Diseases Dependent on Complement Activation, Including Atypical Hemolytic Uremic Syndrome, Membranoproliferative Glomerulonephritis, and C3 Glomerulopathy: Core Curriculum 2015
Marina Noris et al.
AMERICAN JOURNAL OF KIDNEY DISEASES (2015)
Maternal and cord C5a in response to eculizumab Response
Richard M. Burwick et al.
BLOOD (2015)
Eculizumab treatment efficiently prevents C5 cleavage without C5a generation in vivo
Elena B. Volokhina et al.
BLOOD (2015)
Eculizumab reduces complement activation, inflammation, endothelial damage, thrombosis, and renal injury markers in aHUS
Roxanne Cofiell et al.
BLOOD (2015)
Complement activation patterns in atypical haemolytic uraemic syndrome during acute phase and in remission
E. B. Volokhina et al.
CLINICAL AND EXPERIMENTAL IMMUNOLOGY (2015)
Applying complement therapeutics to rare diseases
Edimara S. Reis et al.
CLINICAL IMMUNOLOGY (2015)
Sensitive, reliable and easy-performed laboratory monitoring of eculizumab therapy in atypical hemolytic uremic syndrome
Elena B. Volokhina et al.
CLINICAL IMMUNOLOGY (2015)
Therapeutic drug monitoring of eculizumab: Rationale for an individualized dosing schedule
Philippe Gatault et al.
MABS (2015)
The role of complement in C3 glomerulopathy
Peter F. Zipfel et al.
MOLECULAR IMMUNOLOGY (2015)
A complicated case of atypical hemolytic uremic syndrome with frequent relapses under eculizumab
Gesa Schalk et al.
PEDIATRIC NEPHROLOGY (2015)
Case Report: Benefits and Challenges of Long-term Eculizumab in Atypical Hemolytic Uremic Syndrome
Noelle Cullinan et al.
PEDIATRICS (2015)
Assessing complement blockade in patients with paroxysmal nocturnal hemoglobinuria receiving eculizumab
Regis Peffault de Latour et al.
BLOOD (2015)
Eculizumab hepatotoxicity in pediatric aHUS
Wesley Hayes et al.
PEDIATRIC NEPHROLOGY (2015)
Discontinuation of Eculizumab Maintenance Treatment for Atypical Hemolytic Uremic Syndrome: A Report of 10 Cases
Gianluigi Ardissino et al.
AMERICAN JOURNAL OF KIDNEY DISEASES (2014)
Eculizumab fails to inhibit generation of C5a in vivo
Richard M. Burwick et al.
BLOOD (2014)
Dynamics of complement activation in aHUS and how to monitor eculizumab therapy
Marina Noris et al.
BLOOD (2014)
Polymorphism of the complement receptor 1 gene correlates with the hematologic response to eculizumab in patients with paroxysmal nocturnal hemoglobinuria
Tommaso Rondelli et al.
HAEMATOLOGICA (2014)
Tailored eculizumab regimen for patients with atypical hemolytic uremic syndrome: requirement for comprehensive complement analysis
C. Wehling et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2014)
Complement functional tests for monitoring eculizumab treatment in patients with atypical hemolytic uremic syndrome
M. Cugno et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2014)
Eculizumab in the Treatment of Membranoproliferative Glomerulonephritis
Andrew S. Bomback
NEPHRON CLINICAL PRACTICE (2014)
Genetic Variants in C5 and Poor Response to Eculizumab
Jun-ichi Nishimura et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Antibody-mediated rejection despite inhibition of terminal complement
Andrew Bentall et al.
TRANSPLANT INTERNATIONAL (2014)
Relapse of aHUS after discontinuation of therapy with eculizumab in a patient with aHUS and factor H mutation
Ryan Carr et al.
ANNALS OF HEMATOLOGY (2013)
Targeting the complement system in systemic lupus erythematosus and other diseases
Maria-Louise Barilla-LaBarca et al.
CLINICAL IMMUNOLOGY (2013)
The use of eculizumab in renal transplantation
A. Nicholas R. Barnett et al.
CLINICAL TRANSPLANTATION (2013)
Eculizumab in the treatment of atypical haemolytic uraemic syndrome and other complement-mediated renal diseases
Carla M. Nester et al.
CURRENT OPINION IN PEDIATRICS (2013)
Predictors of hemoglobin response to eculizumab therapy in paroxysmal nocturnal hemoglobinuria
Amy E. DeZern et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2013)
Atypical hemolytic uremic syndrome: From the rediscovery of complement to targeted therapy
Fadi Fakhouri et al.
EUROPEAN JOURNAL OF INTERNAL MEDICINE (2013)
Complement therapy in atypical haemolytic uraemic syndrome (aHUS)
Edwin K. S. Wong et al.
MOLECULAR IMMUNOLOGY (2013)
Eculizumab and recurrent C3 glomerulonephritis
Sevgi Gurkan et al.
PEDIATRIC NEPHROLOGY (2013)
Eculizumab for Salvage Treatment of Refractory Antibody-Mediated Rejection in Kidney Transplant Patients: Case Reports
B. Kocak et al.
TRANSPLANTATION PROCEEDINGS (2013)
Thrombin generates previously unidentified C5 products that support the terminal complement activation pathway
Michael J. Krisinger et al.
BLOOD (2012)
Eculizumab for Dense Deposit Disease and C3 Glomerulonephritis
Andrew S. Bomback et al.
CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2012)
A time for reappraisal of atypical hemolytic uremic syndrome: should all patients be treated the same?
Rebecca L. Ruebner et al.
EUROPEAN JOURNAL OF PEDIATRICS (2012)
Pathology after Eculizumab in Dense Deposit Disease and C3 GN
Leal C. Herlitz et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2012)
Use of eculizumab for atypical haemolytic uraemic syndrome and C3 glomerulopathies
Julien Zuber et al.
NATURE REVIEWS NEPHROLOGY (2012)
Tailored Eculizumab Therapy in the Management of Complement Factor H-Mediated Atypical Hemolytic Uremic Syndrome in an Adult Kidney Transplant Recipient: A Case Report
L. Xie et al.
TRANSPLANTATION PROCEEDINGS (2012)
Design and development of TT30, a novel C3d-targeted C3/C5 convertase inhibitor for treatment of human complement alternative pathway-mediated diseases
Masha Fridkis-Hareli et al.
BLOOD (2011)
Long-term treatment with eculizumab in paroxysmal nocturnal hemoglobinuria: sustained efficacy and improved survival
Richard J. Kelly et al.
BLOOD (2011)
Pre-emptive Eculizumab and Plasmapheresis for Renal Transplant in Atypical Hemolytic Uremic Syndrome
Carla Nester et al.
CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2011)
Molecular Intercommunication between the Complement and Coagulation Systems
Umme Amara et al.
JOURNAL OF IMMUNOLOGY (2010)
Generation of C5a in the absence of C3: a new complement activation pathway
Markus Huber-Lang et al.
NATURE MEDICINE (2006)
Complement activation in infective endocarditis: correlation with extracardiac manifestations and prognosis
IJ Messias-Reason et al.
CLINICAL AND EXPERIMENTAL IMMUNOLOGY (2002)
Share Paper
